Retatrutide, by Soma Corp., is attracting increasing attention as a innovative therapy for obesity regulation. This innovative compound combines the properties of a GLP-1 receptor stimulant and a GIP receptor agonist , intended to not only promote weight loss but also improve associated metabolic is